title: Lenalidomide therapy in del(5)(q31)-associated myelofibrosis: cytogenetic and JAK2V617F molecular remissions.
authors: A
authors: A
authors: Tefferi
authors: T L
authors: TL
authors: Lasho
authors: R A
authors: RA
authors: Mesa
authors: A
authors: A
authors: Pardanani
authors: R P
authors: RP
authors: Ketterling
authors: C A
authors: CA
authors: Hanson
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002872:Chromosome Deletion; D002895:Chromosomes, Human, Pair 5; D020732:Cytogenetic Analysis; D005260:Female; D006801:Humans; D053614:Janus Kinase 2 / Q000235:genetics*; D000077269:Lenalidomide; D008297:Male; D008875:Middle Aged; D017354:Point Mutation / Q000235:genetics*; D055728:Primary Myelofibrosis / Q000188:drug therapy* / Q000235:genetics; D012074:Remission Induction; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D013792:Thalidomide; C507924:JAK2 protein, human; D053614:Janus Kinase 2; D000077269:Lenalidomide